Windlas Biotech Limited Reports its Q1 FY27 Financial Results

Windlas Biotech Limited, one of the leading players in the domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India, reported its unaudited financials for the quarter ended June 30, 2026.

Consolidated Highlights:

Q1FY27 Highlights:

- Revenue from operations stood at Rs 248 crores as against Rs 210 crores, a growth of 18% YoY

- Adjusted EBITDA stood at Rs 34 crores as against Rs 27 crores, a growth of 26% YoY. Adjusted EBITDA Margin came in at 13.6%

- Adjusted PAT stood at Rs 25 crores as against Rs 18 crores, a growth of 37% YoY. PAT Margin came in at 10%

Note:

1) Adjusted EBITDA & Margin and PAT & Margin are excluding the impact of Non-cash ESOP expenses of Rs 7.16 Cr.

2) Reported EBITDA stood at Rs 27 crores. Reported PAT stood at Rs 18 crores.

Commenting on the results Mr. Hitesh Windlass, Managing Director - Windlas Biotech said, "The Indian Pharmaceutical Market (IPM) witnessed a volume growth of 3.4% in Q1 FY27, reflecting a steady yet measured industry environment. Against this backdrop, Windlas Biotech continued its growth trajectory, delivering its highest-ever quarterly revenue of ₹248 crore, representing 18% YoY growth. This performance underscores the strength and resilience of our diversified business model, our operational excellence, and the trust our customers place in us.

We are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturing capacity and enable us to support future growth opportunities. Our Injectables and Plant-2 Extension facilities continue to drive scalable growth, highlighting the effectiveness of our strategic investments.

We remain focused on creating sustainable value through disciplined execution, talent development, client diversification, capability enhancement, and expansion across dosage forms. I would like to thank our customers, partners and employees, shareholders for their continued trust and support."

Adding further, Ms. Komal Gupta, CEO & CFO - Windlas Biotech said, "We have started FY27 with a positive note by extending our record revenue streak to 14 consecutive quarters with 18% YoY growth to Rs 248 crore. Consistent with our focus on long-term shareholders value creation, in Q1 FY27 the company also completed ₹47 crore buyback in which promoters did not participate and declaration of FY26 dividend ₹13 crore (₹6.30 per equity share).

Excluding the impact of ESOP expenses (₹7.2 Crore) which are non-cash in nature, our EBITDA grew 26% YoY to ₹34 crore, PBT and PAT grew 27% and 37% YoY to ₹30 crore and ₹25 crore respectively, reflecting our continued focus on improving operational leverage. If we take into account Non-cash ESOP expenditure (₹7.2 crore), the company reported EBITDA ₹27 crore, PBT ₹23 crore and PAT ₹18 crore. For Q1 FY27 Earnings Per Share (EPS) has improved to ₹ 8.46.

Our Generic Formulations CDMO vertical delivered 29% YoY revenue growth to ₹207 crore, driven by customer expansion, deeper customer engagement, and new product launches. The Trade Generics & Institutional vertical reported revenue of ₹30 crore, following the discontinuation of codeine-based products. As we expand the porƞolio with new launches and replacements, we expect to progressively bridge the gap. Our Exports vertical recorded 79% YoY growth to ₹11 crore. We remain focused on long-term company level performance rather than quarterly and vertical wise fluctuations and are confident in the underlying growth opportunity in all three verticals.

Looking ahead, our priorities remain focused on strengthening strategic partnerships, expanding our offerings, achieving operational excellence, accelerating porƞolio development, and driving disciplined execution. Supported by a modernized manufacturing base, a talented workforce, and a clear strategic direction, we are well positioned to capitalize on the opportunities across all three business verticals."

Shares of Windlas Biotech Ltd was last trading in BSE at Rs. 844.00 as compared to the previous close of Rs. 883.65. The total number of shares traded during the day was 5797 in over 469 trades.

The stock hit an intraday high of Rs. 892.00 and intraday low of 823.70. The net turnover during the day was Rs. 4997056.00.

Source : Equity Bulls

Keywords

WindlasBiotech Q1FY27 Q1FY2027 ResultUpdate